A US health-research chief promoted menopause policy while holding stock in her own menopause startup

Alicia Jackson, the director of the US Advanced Research Projects Agency for Health, publicly endorsed removing the Food and Drug Administration's black-box warning from hormone-replacement therapies while reporting between $115,002 and $300,000 in stock in Evernow, the menopause-treatment platform she founded. She also retained options in the company. The FDA process predated Jackson's appointment, and ProPublica found no evidence that she determined the agency's decision. The conflict is nevertheless concrete: a senior health official used her government position to praise a policy likely to benefit a company in which she remained financially invested.

The disclosures reveal a wider web. Jackson's holding in fertility startup Gameto rose into the $50,001–$100,000 range after the company had received a $10mn ARPA-H award. Her husband owns between $5mn and $25mn in Palantir stock; ARPA-H already had a $19mn Palantir contract and extended it in June by as much as $13.7mn. Jackson also reported interests in more than 60 private-equity and venture funds, at least 13 managed by her husband's firm, 137 Ventures. Her public biography did not mention that relationship.

Dense portfolios are not automatically disqualifying. They require recusals, divestment or a waiver whose scope can be inspected. A draft waiver reportedly allowed Jackson to participate in matters touching more than two dozen investments, but HHS has not produced a final ethics agreement or explained which restrictions are in force. The department has placed her on administrative leave, according to Bloomberg Law.

The institutional failure is therefore one of verifiability. The public can see the assets and the agency decisions but not the operating firewall between them. Recusal rules that exist only in undisclosed paperwork cannot assure grantees, competitors or patients that funding and policy judgements are independent. HHS should publish the final agreement, the covered interests and the record of recusals; anything less asks the public to infer a boundary the department has declined to show.